{"id":921590,"date":"2025-12-19T16:13:14","date_gmt":"2025-12-19T21:13:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/"},"modified":"2025-12-19T16:13:14","modified_gmt":"2025-12-19T21:13:14","slug":"aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/","title":{"rendered":"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WAYNE, Pa., Dec.  19, 2025  (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025.<\/p>\n<p>The NBI is designed to track the performance of a set of securities listed on\u00a0The Nasdaq Stock Market<sup>\u00ae<\/sup> that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.<\/p>\n<p>For more information about the Nasdaq Biotechnology Index, please visit this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xxm_06UlqkJQuS3ifitO27S2yhMlo4fe1Xq3FV1lBnVkyvI3kLznS6QdywYQRjPyjUMgef1ASiI-m3oSJdGQgujeGzXCh6Otk5nzh4kIEQA=\" rel=\"nofollow\" target=\"_blank\"><strong><u>link<\/u><\/strong><\/a>.<\/p>\n<p>\n        <strong>About Aclaris Therapeutics, Inc. <\/strong>\n      <\/p>\n<p>Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&amp;D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tpnm4m93oZeoWB24XosQ-DF2ix_-nlDJ2DqMfjnTuGNEJqS1PGfEtYwgDpW6uMUgzYrCVyXDbZEc6pxqZT4iIw==\" rel=\"nofollow\" target=\"_blank\">X<\/a> (formerly Twitter) at @AclarisTx and on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F3ZZW6Qgq3pgpuSFUDbRnVzj_AdCk-8VxbrtbwrhfqUZRnGlRUkomKytttBhNByq603lUdGg309gXlNkC1JH23Z4nk_NizBWCicsvV_HqFvATyIzRsPNRRqOe6Vo2CSG\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Aclaris Therapeutics Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Will Roberts<\/strong><br \/>\n        <br \/>Senior Vice President<br \/>Corporate Communications and Investor Relations<br \/>(484) 329-2125<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3WfoKlMtwG_DYfMX-4ifxHPMtYyEjdaZBM3bO4tFEpXXSNjzAcAzkxz30P2mcjAIIVwROlOLyNUSNkVE8JpYgJcvFyY9PnqvtBegBPh5ezw=\" rel=\"nofollow\" target=\"_blank\">wroberts@aclaristx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzBiNzY2YWQtMmQ3Ni00MDg2LWI4NGUtNjAzMmMzNThiOWQ3LTEwMzE3NTUtMjAyNS0xMi0xOS1lbg==\/tiny\/Aclaris-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025. The NBI is designed to track the performance of a set of securities listed on\u00a0The Nasdaq Stock Market\u00ae that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-921590","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025. The NBI is designed to track the performance of a set of securities listed on\u00a0The Nasdaq Stock Market\u00ae that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted &hellip; Continue reading &quot;Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-19T21:13:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)\",\"datePublished\":\"2025-12-19T21:13:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/\"},\"wordCount\":225,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/\",\"name\":\"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=\",\"datePublished\":\"2025-12-19T21:13:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/","og_locale":"en_US","og_type":"article","og_title":"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - Market Newsdesk","og_description":"WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025. The NBI is designed to track the performance of a set of securities listed on\u00a0The Nasdaq Stock Market\u00ae that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted &hellip; Continue reading \"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-19T21:13:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)","datePublished":"2025-12-19T21:13:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/"},"wordCount":225,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/","name":"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=","datePublished":"2025-12-19T21:13:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNTIyNyM3MzMwODQ0IzIwMjAxODM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-added-to-the-nasdaq-biotechnology-index-nbi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=921590"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921590\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=921590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=921590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=921590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}